Subscribe to RSS
DOI: 10.1055/a-1063-6377
Update on “Associations of Estrogen Receptor Alpha Gene Polymorphisms with Type 2 Diabetes Mellitus and Metabolic Syndrome: A Systematic Review and Meta-Analysis”
Publication History
Publication Date:
16 January 2020 (online)
Dear Editor,
Yang et al. [1] published a meta-analysis on the association of ESR1 (estrogen receptor alpha) polymorphism and the risk of type 2 diabetes mellitus (T2DM). Based on to their findings, recessive model ESR1 rs2234693 polymorphism (OR=0.673, 95 % CI=0.550–0.823, p random-effect model<0.001, p fixed-effect model<0.003) was significantly associated with the susceptibility to T2DM.
However, there are some mistype on the genetic models, it should be written recessive model rather than the regressive model in the manuscript. Moreover, in this letter, I also update the results of the meta-analysis for the association between ESR1 polymorphisms with T2DM. In this present study, two studies published by Akhmad et al. [2] and Ereqat et al. [3] are included ([Table 1]). It showed that no associations were observed between ESR1 rs2234693 or rs9340799 polymorphisms with T2DM ([Tables 2] and [3]). However, when the two studies from ESR1 rs2234693 in which the genotype distribution for the control groups deviated from HWE were excluded, a significant association was observed in the homozygous model (CC vs. TT, OR=0.64; 95% CI 0.47–0.88, p=0.006, I2=39.15%) ([Table 2], [Fig. 1]). No change was observed from ESR1 rs9340799, although three studies deviated from HWE were excluded ([Table 3]). No publication bias was observed among studies (p>0.05, data now shown). Together, these results suggest that homozygous of CC genotype ESR1 rs2234693 shows a protective effect against T2DM. Indeed, the estrogen receptor and its signaling play an important role in regulating insulin sensitivity [4]. Nevertheless, more studies, especially for ESR1 rs2234693, are needed to verify these results.
rs2234693 (PvuII) |
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. |
Author [Ref] |
Year |
Country |
Sample size (T2DM/Control) |
Genotype distribution T2DM |
Control |
PHWE * |
Allele distribution T2DM |
Control |
||||||
TT |
TC |
CC |
TT |
TC |
CC |
T |
C |
T |
C |
||||||
1 |
Akhmad et al. [2] |
2013 |
Indonesia |
40/25 |
9 |
18 |
13 |
4 |
14 |
4 |
0.2008 |
44 |
36 |
22 |
28 |
2 |
Chen et al. [5] |
2015 |
China |
20/40 |
4 |
10 |
6 |
4 |
25 |
11 |
0.0671 |
18 |
22 |
33 |
47 |
3 |
Dong et al. [6] |
2002 |
China |
104/60 |
16 |
62 |
25 |
7 |
26 |
27 |
0.8465 |
95 |
113 |
40 |
80 |
4 |
Ereqat et al. [3] |
2019 |
Palestine |
102/112 |
27 |
57 |
18 |
43 |
47 |
22 |
0.1685 |
111 |
93 |
133 |
91 |
5 |
Ganasyam et al. [7] |
2012 |
India |
100/100 |
39 |
43 |
18 |
52 |
32 |
16 |
0.0081 |
121 |
79 |
136 |
64 |
6 |
Huang et al. [8] |
2006 |
China |
299/341 |
36 |
172 |
91 |
34 |
149 |
158 |
0.8962 |
224 |
354 |
217 |
465 |
7 |
Meshkani et al. [9] |
2012 |
Iran |
152/299 |
52 |
73 |
27 |
64 |
173 |
62 |
0.0065 |
177 |
127 |
301 |
297 |
8 |
Mohammadi et al. [10] |
2013 |
Iran |
174/174 |
50 |
67 |
57 |
25 |
84 |
65 |
0.7981 |
167 |
181 |
134 |
214 |
9 |
Motawi et al. [11] |
2015 |
Egypt |
90/40 |
24 |
49 |
17 |
15 |
19 |
6 |
0.9967 |
97 |
83 |
49 |
31 |
rs9340799 (XbaI) |
|||||||||||||||
No. |
Author [Ref] |
Year |
Country |
Sample size (T2DM/Control) |
Genotype distribution T2DM |
Control |
P HWE * |
Allele distribution T2DM |
Control |
||||||
AA |
AG |
GG |
AA |
AG |
GG |
A |
G |
A |
G |
||||||
1 |
Akhmad et al. [2] |
2013 |
Indonesia |
40/25 |
4 |
25 |
11 |
18 |
33 |
14 |
0.8767 |
47 |
33 |
61 |
69 |
2 |
Chen et al. [5] |
2015 |
China |
20/40 |
3 |
5 |
12 |
8 |
25 |
7 |
0.1127 |
11 |
29 |
41 |
39 |
3 |
Dong et al. [6] |
2002 |
China |
104/60 |
11 |
74 |
19 |
21 |
38 |
1 |
0.001 |
96 |
112 |
80 |
40 |
4 |
Ereqat et al. [3] |
2019 |
Palestine |
102/112 |
44 |
44 |
24 |
40 |
101 |
73 |
0.6284 |
132 |
92 |
247 |
118 |
5 |
Ganasyam et al. [7] |
2012 |
India |
100/100 |
5 |
20 |
75 |
4 |
10 |
86 |
0.0001 |
30 |
170 |
22 |
186 |
6 |
Huang et al. [8] |
2006 |
China |
299/341 |
33 |
149 |
117 |
33 |
158 |
150 |
0.3526 |
383 |
215 |
458 |
214 |
7 |
Meshkani et al. [9] |
2012 |
Iran |
152/299 |
57 |
68 |
27 |
76 |
167 |
56 |
0.0348 |
182 |
122 |
319 |
279 |
8 |
Mohammadi et al. [10] |
2013 |
Iran |
174/174 |
53 |
60 |
61 |
24 |
77 |
73 |
0.6096 |
166 |
182 |
125 |
223 |
9 |
Motawi et al. [11] |
2015 |
Egypt |
90/40 |
34 |
39 |
17 |
20 |
15 |
5 |
0.4209 |
55 |
25 |
107 |
73 |
10 |
Speer et al. [12] |
2001 |
Hungary |
49/138 |
22 |
25 |
2 |
20 |
88 |
30 |
0.0009 |
69 |
29 |
128 |
148 |
* p-Values for Hardy–Weinberg equilibrium test in controls.
All relevant articles were included (n=9) |
||||||
---|---|---|---|---|---|---|
Contrast |
Test of association |
Model* |
Test of heterogeneity |
|||
OR |
95% CI |
p |
p |
I2 (%) |
||
C vs. T |
0.88 |
[0.70; 1.09] |
0.26 |
Random |
0.0056 |
63.08 |
CC vs. CT+TT |
0.78 |
[0.58; 1.04] |
0.09 |
Random |
0.0632 |
45.94 |
CC+CT vs. TT |
0.87 |
[0.57; 1.31] |
0.51 |
Random |
0.0008 |
70.03 |
CC vs. TT |
0.73 |
[0.50; 1.07] |
0.11 |
Random |
0.0712 |
44.56 |
CT vs. TT |
0.92 |
[0.59; 1.44] |
0.73 |
Random |
0.0005 |
71.20 |
Articles deviated for HWE were excluded (n=7) |
||||||
Contrast |
Test of association |
Model * |
Test of heterogeneity |
|||
OR |
95% CI |
p |
p |
I2 (%) |
||
C vs. T |
0.85 |
[0.66; 1.09] |
0.21 |
Random |
0.0257 |
58.26 |
CC vs. CT+TT |
0.74 |
[0.51; 1.07] |
0.11 |
Random |
0.0558 |
51.19 |
CC+CT vs. TT |
0.85 |
[0.53; 1.37] |
0.51 |
Random |
0.013 |
62.85 |
CC vs. TT |
0.64 |
[0.47; 0.88] |
0.006 |
Fixed |
0.1307 |
39.15 |
CT vs. TT |
0.92 |
[0.55; 1.55] |
0.76 |
Random |
0.0082 |
65.32 |
* If the p-value for Q-statistic was<0.10 or the I2 value ≥50%, random-effect model was used, otherwise fixed-effect model was adopted.
All relevant articles were included (n=10) |
|||||||
---|---|---|---|---|---|---|---|
Contrast |
Test of association |
Model* |
Test of heterogeneity |
||||
OR |
95% CI |
p |
p |
I2 (%) |
|||
G vs. A |
0.91 |
[0.65; 1.27] |
0.604 |
Random |
0.0001 |
85.36 |
|
GG vs. TC+CC |
0.94 |
[0.62; 1.43] |
0.794 |
Random |
0.0002 |
72.04 |
|
GG+AG vs. AA |
0.84 |
[0.48; 1.46] |
0.541 |
Random |
0.0001 |
84.24 |
|
GG vs. AA |
0.89 |
[0.45; 1.73] |
0.738 |
Random |
0.0001 |
81.03 |
|
GA vs. AA |
0.82 |
[0.48; 1.40] |
0.479 |
Random |
0.0001 |
80.20 |
|
Articles deviated for HWE were excluded (n=7) |
|||||||
Contrast |
Test of association |
Model* |
Test of heterogeneity |
||||
OR |
95% CI |
p |
p |
I2 (%) |
|||
G vs A |
0.93 |
[0.68; 1.28] |
0.688 |
Random |
0.0001 |
80.21 |
|
GG vs. TC+CC |
1.00 |
[0.67; 1.47] |
0.993 |
Random |
0.0065 |
66.48 |
|
GG+AG vs. AA |
0.77 |
[0.46; 1.29] |
0.335 |
Random |
0.0002 |
76.98 |
|
GG vs. AA |
0.85 |
[0.46; 1.55] |
0.608 |
Random |
0.0004 |
75.91 |
|
GA vs. AA |
0.72 |
[0.44; 1.18] |
0.198 |
Random |
0.0017 |
71.77 |
* If the p-value for Q-statistic was<0.10 or the I2 value ≥ 50%, random-effect model was used, otherwise fixed-effect model was adopted.
-
References
- 1 Yang J, Han R, Chen M. et al. Associations of estrogen receptor alpha gene polymorphisms with type 2 diabetes mellitus and metabolic syndrome: a systematic review and meta-analysis. Horm Metab Res 2018; 50: 469-477
- 2 Akhmad S, Madiyan M, Hastuti P. et al. Estrogen receptor alpha (Esr) gene polymorphism as risk factor for type 2 diabetes mellitus (T2dm) in Javenese menopause women of Indonesia. Bangladesh J Med Sci. 2013; 12: 172-179
- 3 Ereqat S, Cauchi S, Eweidat K. et al. Estrogen receptor 1 gene polymorphisms (PvuII and XbaI) are associated with type 2 diabetes in Palestinian women. Peer J 2019; 7: e7164
- 4 Ulhaq ZS. Estrogen – serotonin interaction and its implication on insulin resistance. Alexandria J Med. 2019; 55: 76-81
- 5 Chen DL, Wang SZ. Exploration on the relationship between the polymorphism of estrogen receptor (ER) gene and bone density in diabetic patients. Med Inform 2015; 28: 302
- 6 Dong JH, Liu L, Li CG. et al. Study on the relationship between estrogen receptor gene polymorphism and bone mineral density in diabetic patients. Chin J Endocrinol Metab 2002; 18: 214-218
- 7 Ganasyam SR, Rao TB, Murthy YS. et al. Association of estrogen receptor-α gene & metallothionein-1 gene polymorphisms in type 2 diabetic women of Andhra Pradesh. Indian J Clin Biochem. 2012; 27: 69-73
- 1 Huang Q, Wang TH, Lu WS. et al. Estrogen receptor alpha gene polymorphism associated with type 2 diabetes mellitus and the serum lipid concentration in Chinese women in Guangzhou. Chin Med J (Engl) 2006; 119: 1794-1801
- 9 Meshkani R, Saberi H, MohammadTaghvaei N. et al. Estrogen receptor alpha gene polymorphisms are associated with type 2 diabetes and fasting glucose in male subjects. Mol Cell Biochem. 2012; 359: 225-233
- 7 Mohammadi F, Pourahmadi M, Mosalanejad M. et al. Association of estrogen receptor α genes PvuII and XbaI polymorphisms with type 2 diabetes mellitus in the inpatient population of a hospital in Southern Iran. Diabetes Metab J. 2013; 37: 270-277
- 11 Motawi TM, El-Rehany MA, Rizk SM. et al. Genetic polymorphism of estrogen receptor alpha gene in Egyptian women with type II diabetes mellitus. Meta Gene. 2015; 6: 36-41
- 12 Speer G, Cseh K, Winkler G. et al. Vitamin D and estrogen receptor gene polymorphisms in type 2 diabetes mellitus and in android type obesity. Eur J Endocrinol. 2011; 144: 385-389